TAITA Seminar, Thursday Evening, March 11, 2010
Panel Topic: Finding multiple faces of biomedical business and niche market with a perspective view from antibodies and peptides
Moderator: Robert (Rong Ming) Lyu, Ph. D. Panelists : John C. Lin, M.D., Ph.D.
Executive Director, Rinat, Pfizer Inc.; Anita Hong, Ph. D, President/CEO of AnaSpec and RonHwa Lin, Dr. rer. nat, President/CEO of AbGenomics International, Inc.
Date/Time: 3/11/10 (Thursday) 6:30 pm– 9:00 pm
Location: Fenwick & West LLP, Silicon Valley Center , 801 California St. , Mt. View , CA
Fee: $5 for TAITA’s members, $10 for non-members.
Contact: Robert (Rong Ming) Lyu, Phoenix Pharmaceuticals < lyu786@yahoo.com>
More information on TAITA's Website (www.taita.us).
Plenty of finger foods with soft drinks provided
Topic Discussion
Biomedical business has big opportunity due to a great demand from "ageing population" and the arriving of “health reform”. Can opportunity to gain knowledge for promoting your health also probably bring you a wealth? Business with antibody and peptide are good examples with two-digit numbers growth in the last decade and can be better for next
decade. Especially, (1) Antibodies are good diagnostic tools and also becoming important new drugs for diseases. There are 22 therapeutic monoclonal antibodies on the market and several hundred of monoclonal antibody either in human clinical trials or under review by the
US FDA. The size of therapeutic antibody is projected to reach between $26 and $39 billion at 2010. (2) Advances in peptide synthesis, delivery, and formulation techniques, peptides applications has become more mature and broad. Since yr 2000 the number of therapeutic
peptides in clinical trial has doubled compared to the 1990s. Disregard the $3.5 billion anti-aging cosmedceuticals industry, the study goes on to note that 48 therapeutic peptides are now on the market worldwide, with 4 having generated global sales of more than $500 million each in 2007. Approximately 400 therapeutic peptides are now
moving through the clinical trial process. What are the true drivers of new development? What are the challenges? What is the short- and long term market outlook? "Here are three highly accredited panelists will share their views for the coming niches.
Speaker Bios
John C. Lin, M.D., Ph.D.completed M.D. from National Taiwan University in 1992, and received Ph.D. from Harvard University in 1998. After postdoctoral work at Genentech in 2001, he joined Rinat Neuroscience Corp., a biotech start-up developing novel antibody therapies for pain and Alzheimer's disease. He has joined Pfizer Inc. since 2006 when Pfizer acquired Rinat to expand their biotherapeutic portfolio. Dr. Lin is author of numerous publications and inventor of several US and international patents on neurology, metabolic disorders and autoimmunity. He served as grant reviewer for Michael J Fox Foundation for Parkinson's Research since 2006. He served as Board Director of TAITA-SV from 2007-2008.
Anita Hong, Ph. D. received her Ph.D. in Physical Organic Chemistry from the University of Alberta in 1970. After worked in the Beckman Instruments, Inc. for eight years in Palo Alto , she worked for Applied Biosystems, Inc. (ABI) to establish the custom peptide synthesis group. In 1993, together with her husband, Dr. Frank Hong, she founded AnaSpec, Inc. in San Jose , CA. AnaSpec was initially conceived as simply a peptide synthesis service company; however, through expansion into complementary fields such as antibodies and technologies, it has since diversified into a multifaceted product/service company. In 2003, AnaSpec acquired HiLyte Biosciences, a developer and manufacturer of fluorescence detection reagents. At Oct. 2009, AnaSpec was acquired by Eurogentic. However, she will remain aboard the company in leading role in continuing to grow AnaSpec’s business.
Rong Hwa Lin, Dr. rer. Nat after receiving a Dr. rer.nat (Immunology) degree from Tubingen University and Post-Doc. in Basel Institute for Immunology in Switzerland and Horward Hughes Medical Institute at Yale, he served as Professor and Director of Graduate
Institute of Immunology, Medical School , National Taiwan University . In 2000, he founded Abgenomics and began developing and marketing therapeutic monoclonal antibody at Taipei . Within only 10 years since, his company discovered more than 4 potential therapeutic candidates. The first drug candidate AbGn-168 has licensed to Boehringer Ingelheim in 2005 and start Phase I trial on March, 2009. To explore into other business arena, the company has reorganised and established its US headquarters, AbGenomics International Inc, in 2006. In this March 11, Dr. Lin will discuss his experience of establishing a company and the target-oriented monoclonal antibodies in various stages of pre-clinical and clinical studies. Let us explore the reasons why many bay area companies like Abgenix, PDL, Medarex and Rinat has been transformed by big pharma and prepare well for the changes in the coming decade.
